Combined Targeted Therapies for First-line Treatment of Metastatic Triple Negative Breast Cancer—A Phase II Trial of Weekly Nab-Paclitaxel and Bevacizumab Followed by Maintenance Targeted Therapy With Bevacizumab and Erlotinib
- 1 April 2019
- journal article
- research article
- Published by Elsevier in Clinical Breast Cancer
- Vol. 19 (2) , e283-e296
Abstract
No abstract availableKeywords
Funding Information
- Genentech (OSI4266s)
- Celegene (AX-CL-BRST-PI-003828)
- National Cancer Institute (P30CA015704, P30CA047904)
This publication has 43 references indexed in Scilit:
- Cancer statistics, 2018CA: A Cancer Journal for Clinicians, 2018
- Efficacy and Safety of Bevacizumab Combined with Chemotherapy for Managing Metastatic Breast Cancer: A Meta-Analysis of Randomized Controlled TrialsScientific Reports, 2015
- Changing Treatment Paradigms in Metastatic Breast CancerJAMA Oncology, 2015
- Sequential Application of Anticancer Drugs Enhances Cell Death by Rewiring Apoptotic Signaling NetworksCell, 2012
- Clinical value of circulating endothelial cells and circulating tumor cells in metastatic breast cancer patients treated first line with bevacizumab and chemotherapyAnnals of Oncology, 2010
- A Phase II Trial of Erlotinib in Combination with Bevacizumab in Patients with Metastatic Breast CancerClinical Cancer Research, 2008
- Circulating endothelial cells in oncology: pitfalls and promisesBritish Journal of Cancer, 2008
- TRIBUTE: A Phase III Trial of Erlotinib Hydrochloride (OSI-774) Combined With Carboplatin and Paclitaxel Chemotherapy in Advanced Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2005
- Circulating Tumor Cells, Disease Progression, and Survival in Metastatic Breast CancerNew England Journal of Medicine, 2004
- The Pathology of Familial Breast Cancer: Predictive Value of Immunohistochemical Markers Estrogen Receptor, Progesterone Receptor, HER-2, and p53 in Patients With Mutations in BRCA1 and BRCA2Journal of Clinical Oncology, 2002